Because of low ctDNA abundance in advanced adenoma and early CRC, the developed tests generally show more promise as the tools for treatment decision making in metastatic CRC, including the information about the combined use of conventional and targeted drugs, such as antibodies against VEGF or EGFR, multikinase inhibitors, and immune checkpoint inhibitors. The gene discussed is VEGFA; the disease is colorectal carcinoma.